Simplify Asset Management Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Simplify Asset Management Inc.

  • $1.77 Billion
  • Q3 2025

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025
SELL
$31.06 - $39.3 $52,491 - $66,417
-1,690 Reduced 10.0%
15,210 $553,000
Q1 2025

May 13, 2025
BUY
$36.21 - $45.78 $3,258 - $4,120
90 Added 0.54%
16,900 $611,000
Q4 2024

Feb 11, 2025
BUY
$42.07 - $57.72 $707,196 - $970,273
16,810 New
16,810 $707,000
Q2 2024

Aug 12, 2024
SELL
$37.42 - $51.61 $3,816 - $5,264
-102 Reduced 0.33%
30,651 $1.26 Million
Q1 2024

May 13, 2024
BUY
$43.02 - $53.69 $1.32 Million - $1.65 Million
30,753 New
30,753 $1.44 Million

Others Institutions Holding RARE

# of Institutions
348
Shares Held
88.2M
Call Options Held
2.19M
Put Options Held
1.04M
View Full List

About Ultragenyx Pharmaceutical Inc.

RARE Quotes by TradingView
  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.32B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Simplify Asset Management Inc. Portfolio

Follow Simplify Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplify Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Simplify Asset Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email